
HCAT Stock Forecast & Price Target
HCAT Analyst Ratings
Bulls say
Health Catalyst is facing temporary headwinds due to its transition and restructuring within its professional services segment, leading to a decrease in revenue in the short term. However, its strong customer retention and potential for divestitures in its application assets position the company for long-term growth and profitability. Despite some challenges in the end market and negative mix shift, Health Catalyst's flagship offering and recurring revenue from its applications provide stability and potential for shareholder value.
Bears say
Health Catalyst is currently facing several challenges, including a decrease in FY27 revenue and adj. EBITDA estimates, as well as a step down in revenue from 2Q26 guidance due to DOS-to-Ignite migration/down-sell risk and broader ARR retention pressure. Additionally, the health system end-market is facing financial pressure which could reduce the budget availability for technology investments, potentially leading to decreased demand for Health Catalyst's offerings. In terms of competition, the company faces both home-grown solutions from health systems and competition from larger technology and EHR companies in the data platform and warehouse space, as well as from consultancies in the services segment.
This aggregate rating is based on analysts' research of Health Catalyst Inc and is not a guaranteed prediction by Public.com or investment advice.
HCAT Analyst Forecast & Price Prediction
Start investing in HCAT
Order type
Buy in
Order amount
Est. shares
0 shares